دورية أكاديمية
أعرض في EDS

Assessment of the Effect of Leonurine Hydrochloride in a Mouse Model of PCOS by Gene Expression Profiling.

التفاصيل البيبلوغرافية
العنوان: Assessment of the Effect of Leonurine Hydrochloride in a Mouse Model of PCOS by Gene Expression Profiling.
المؤلفون: Wang M; College of Animal Science and Technology, Shihezi University, Shihezi 832000, China., Yang L; College of Veterinary Medicine, Xinjiang Agricultural University, Urumqi 830052, China., Sun G; College of Animal Science and Technology, Shihezi University, Shihezi 832000, China., Shao Y; College of Animal Science and Technology, Shihezi University, Shihezi 832000, China., Liu Y; College of Animal Science and Technology, Shihezi University, Shihezi 832000, China., Yang H; College of Animal Science and Technology, Shihezi University, Shihezi 832000, China., Wang Y; College of Animal Science and Technology, Shihezi University, Shihezi 832000, China., Zhang M; College of Animal Science and Technology, Shihezi University, Shihezi 832000, China., Shang Y; College of Animal Science and Technology, Shihezi University, Shihezi 832000, China., Gu X; College of Animal Science and Technology, Shihezi University, Shihezi 832000, China.
المصدر: Genes [Genes (Basel)] 2024 Apr 18; Vol. 15 (4). Date of Electronic Publication: 2024 Apr 18.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101551097 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4425 (Electronic) Linking ISSN: 20734425 NLM ISO Abbreviation: Genes (Basel) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel : MDPI
مواضيع طبية MeSH: Gallic Acid*/*analogs & derivatives, Polycystic Ovary Syndrome*/genetics , Polycystic Ovary Syndrome*/drug therapy , Polycystic Ovary Syndrome*/metabolism , Disease Models, Animal* , Gallic Acid*/pharmacology, Animals ; Female ; Mice ; Luteinizing Hormone/blood ; Ovary/metabolism ; Ovary/drug effects ; Ovary/pathology ; Follicle Stimulating Hormone/blood ; Gene Expression Profiling ; Testosterone/blood ; Transcriptome
مستخلص: Polycystic ovary syndrome (PCOS) is an endocrine disease commonly associated with metabolic disorders in females. Leonurine hydrochloride (Leo) plays an important role in regulating immunity, tumours, uterine smooth muscle, and ovarian function. However, the effect of Leo on PCOS has not been reported. Here, we used dehydroepiandrosterone to establish a mouse model of PCOS, and some mice were then treated with Leo by gavage. We found that Leo could improve the irregular oestros cycle of PCOS mice, reverse the significantly greater serum testosterone (T) and luteinising hormone (LH) levels, significantly reduce the follicle-stimulating hormone (FSH) level, and significantly increase the LH/FSH ratio of PCOS mice. Leo could also change the phenomenon of ovaries in PCOS mice presented with cystic follicular multiplication and a lacking corpus luteum. Transcriptome analysis identified 177 differentially expressed genes related to follicular development between the model and Leo groups. Notably, the cAMP signalling pathway, neuroactive ligand-receptor interactions, the calcium signalling pathway, the ovarian steroidogenesis pathway, and the Lhcgr , Star , Cyp11a , Hsd17b7 , Camk2b , Calml4, and Phkg1 genes may be most related to improvements in hormone levels and the numbers of ovarian cystic follicles and corpora lutea in PCOS mice treated by Leo, which provides a reference for further study of the mechanism of Leo.
References: Obstet Gynecol Surv. 2002 Nov;57(11):755-67. (PMID: 12447098)
OMICS. 2012 May;16(5):284-7. (PMID: 22455463)
Hum Reprod. 2004 Jan;19(1):41-7. (PMID: 14688154)
Dev Dyn. 2008 Mar;237(3):527-44. (PMID: 18265018)
J Clin Endocrinol Metab. 2006 Nov;91(11):4237-45. (PMID: 16940456)
Endocr Rev. 2012 Dec;33(6):981-1030. (PMID: 23065822)
Oxid Med Cell Longev. 2021 Aug 3;2021:9919466. (PMID: 34394836)
Genes (Basel). 2022 Mar 27;13(4):. (PMID: 35456401)
J Endocrinol. 2002 Jul;174(1):1-5. (PMID: 12098657)
Mol Med Rep. 2020 May;21(5):2138-2150. (PMID: 32323770)
Pharmacol Ther. 2018 Aug;188:26-35. (PMID: 29360539)
Endocr J. 2019 Oct 28;66(10):859-870. (PMID: 31270279)
Physiol Rev. 2006 Jan;86(1):25-88. (PMID: 16371595)
Hum Mol Genet. 1997 Mar;6(3):397-402. (PMID: 9147642)
Reprod Biol Endocrinol. 2018 Oct 19;16(1):99. (PMID: 30340496)
Endocr Rev. 2015 Oct;36(5):487-525. (PMID: 26426951)
Theriogenology. 2023 Mar 15;199:11-18. (PMID: 36680865)
Evid Based Complement Alternat Med. 2021 Jul 08;2021:5577610. (PMID: 34306142)
Nat Biotechnol. 2013 Jan;31(1):46-53. (PMID: 23222703)
Clin Endocrinol (Oxf). 2004 Jan;60(1):1-17. (PMID: 14678281)
Reprod Biomed Online. 2016 Jun;32(6):635-41. (PMID: 27061682)
Oxid Med Cell Longev. 2020 Nov 26;2020:3648040. (PMID: 33294120)
Theriogenology. 2020 Oct 15;156:116-123. (PMID: 32698037)
Sci Rep. 2016 Dec 07;6:38134. (PMID: 27924832)
Heliyon. 2020 Jul 28;6(7):e04279. (PMID: 32760818)
Ann N Y Acad Sci. 2003 Nov;997:42-8. (PMID: 14644808)
Trends Endocrinol Metab. 2018 May;29(5):313-325. (PMID: 29602523)
Front Physiol. 2016 Aug 30;7:371. (PMID: 27625611)
Genes (Basel). 2022 Dec 07;13(12):. (PMID: 36553574)
Inflammation. 2020 Feb;43(1):146-154. (PMID: 31659586)
Genes (Basel). 2019 Feb 18;10(2):. (PMID: 30781725)
Toxicology. 2019 Jun 15;422:1-13. (PMID: 31005592)
Int Immunopharmacol. 2023 Jan;114:109520. (PMID: 36513022)
Endocr Rev. 2011 Feb;32(1):81-151. (PMID: 21051590)
Life Sci. 2017 Dec 15;191:259-272. (PMID: 29055801)
Phytother Res. 2022 May;36(5):2161-2172. (PMID: 35285100)
Reproduction. 2010 Apr;139(4):685-95. (PMID: 20089664)
Brain Behav. 2021 Feb;11(2):e01995. (PMID: 33300684)
Pathol Oncol Res. 2020 Jan;26(1):575-582. (PMID: 31278444)
PLoS One. 2015 Mar 19;10(3):e0120170. (PMID: 25790350)
Endocrinology. 2014 Apr;155(4):1445-52. (PMID: 24527662)
Nat Rev Endocrinol. 2011 Apr;7(4):219-31. (PMID: 21263450)
Clin Epigenetics. 2019 Apr 11;11(1):61. (PMID: 30975191)
PLoS Genet. 2015 Aug 25;11(8):e1005455. (PMID: 26305227)
Endocr Rev. 2005 Apr;26(2):251-82. (PMID: 15561799)
Biomolecules. 2022 Oct 19;12(10):. (PMID: 36291721)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Fitoterapia. 2022 Mar;157:105108. (PMID: 34954263)
Nat Methods. 2015 Apr;12(4):357-60. (PMID: 25751142)
J Ovarian Res. 2019 Nov 13;12(1):109. (PMID: 31722718)
Can Med Assoc J. 1966 Jan 1;94(1):1-7. (PMID: 5901591)
Front Pharmacol. 2021 Apr 16;12:657724. (PMID: 33935775)
Hum Reprod. 2016 Apr;31(4):774-81. (PMID: 26908843)
Fertil Steril. 2012 Jan;97(1):28-38.e25. (PMID: 22153789)
PLoS One. 2015 Apr 08;10(4):e0124003. (PMID: 25853886)
J Surg Res. 2020 Jan;245:453-460. (PMID: 31445497)
Front Endocrinol (Lausanne). 2019 Dec 13;10:879. (PMID: 31920988)
Br J Pharmacol. 2022 Sep;179(18):4563-4574. (PMID: 35751868)
Front Genet. 2021 May 18;12:648701. (PMID: 34084179)
فهرسة مساهمة: Keywords: dehydroepiandrosterone; leonurine hydrochloride; polycystic ovary syndrome; transcriptome
المشرفين على المادة: 09Q5W34QDA (leonurine)
632XD903SP (Gallic Acid)
9002-67-9 (Luteinizing Hormone)
9002-68-0 (Follicle Stimulating Hormone)
3XMK78S47O (Testosterone)
تواريخ الأحداث: Date Created: 20240427 Date Completed: 20240427 Latest Revision: 20240611
رمز التحديث: 20240611
مُعرف محوري في PubMed: PMC11050333
DOI: 10.3390/genes15040507
PMID: 38674441
قاعدة البيانات: MEDLINE
الوصف
تدمد:2073-4425
DOI:10.3390/genes15040507